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Abstract
Background:  Vascular permeability factor/Vascular endothelial growth factor (VPF/VEGF), a
multifunctional cytokine, is a potent inducer of vascular permeability, an important early step in
angiogenesis. It is known that the neurotransmitter dopamine can inhibit VPF/VEGF mediated
angiogenesis, in particular microvascular permeability, but the effectors of this action remain
unclear.
Results: Here, we define the signaling pathway modulated by dopamine that inhibits VPF/VEGF
induced vascular permeability in endothelial cells. Signals from VPF/VEGF lead to changes in the
phosphorylation of tight junction protein zonula occludens (ZO-1) and adherens junction proteins
like VE-cadherin and associated catenins, thus weakening endothelial cell-cell adhesion and
increasing vascular permeability. We found VEGF receptor-2 (VEGFR-2) to be part of a multi-
protein complex involving ZO-1, VE-cadherin and β-catenin. VPF/VEGF induced phosphorylations
of VE-cadherin, β-catenin and ZO-1 were inhibited by dopamine treatment. Association of occludin
with ZO-1 and ZO-1 with VE-cadherin were significantly inhibited by dopamine in VEGF treated
cells. Furthermore, we identified Src as an important target for dopamine-mediated inhibition of
VPF/VEGF induced permeability.
Conclusion: Taken together, our results provide molecular insights of dopamine function in the
vascular endothelium and suggest a central role of Src in regulating key molecules that control
vascular permeability.
Background
Vascular permeability factor/vascular endothelial growth
factor (VPF/VEGF) is a multifunctional cytokine that plays
a critical role in angiogenesis [1-3]. It is a pleiotropic
growth factor that mediates multiple functions via stimu-
lation of its cognate receptors on endothelial cells [1-3].
VPF/VEGF was originally described as a tumor-secreted
protein that renders venules and small veins hyperperme-
able to circulating macromolecules and was, therefore,
initially termed vascular permeability factor [1-5]. In fact,
VPF/VEGF is one of the most potent inducers of vascular
permeability known. It is 50,000-fold more potent than
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histamine [1,3-6]. This ability to enhance microvascular
permeability remains one of the most important proper-
ties of VPF/VEGF, especially with regard to the hyperper-
meability of tumor vessels that is attributable to tumor
cell expression of VPF/VEGF [1,3-6]. Furthermore, it has
been suggested that the increase in permeability results in
the leakage of several plasma proteins, including fibrino-
gen and other clotting proteins. This can lead to the dep-
osition of fibrin in the extravascular space, which
subsequently retards the clearance of edema fluid and
transforms the normally antiangiogenic stroma of normal
tissues into a proangiogenic environment [1,3-5]. VPF/
VEGF increases permeability in a variety of vascular beds
– including those of the skin, peritoneal wall, mesentery,
and diaphragm – and can lead to pathologic conditions
such as malignant ascites [3,7] and malignant pleural
effusions [3,8]. In fact, there is evidence that inhibition of
VPF/VEGF can lead to decreased formation of pleural effu-
sions [3,8] and that antibodies directed against VPF/VEGF
or VEGFR-2 can lead to a decrease in tumor vessel perme-
ability and ascites formation [1,3,8-10].
Vascular permeability, as induced by VPF/VEGF, is due to
its action on the endothelium. Endothelial cell-to-cell
junctions are complex structures formed by different
adhesive molecules [11,12]. Endothelial cells have tight
junctions (TJ) and adherens junctions (AJ). AJ are formed
by transmembrane proteins that belong to the cadherin
superfamily such as vascular endothelial VE-cadherin
[11,13]. These proteins are linked inside the cells to β-cat-
enin and plakoglobin that in turn, through the binding to
α-catenin, promote anchorage to the actin cytoskeleton
and are required for full control of junctional permeabil-
ity [14]. TJ, in contrast, are formed by three different types
of transmembrane proteins: occludin [15], claudins [16],
and junctional adhesion molecule (JAM) [17]. Inside the
cells, several cytoskeletal signaling molecules are concen-
trated in the TJ area, such as ZO-1, cingulin, and 7H6
[18,19].
We have recently demonstrated that dopamine signifi-
cantly and specifically inhibits VPF/VEGF induced vascu-
lar permeability in the endothelial cells in vivo [20-23].
However, the effectors by which dopamine mediates this
action is unclear [20-23]. VPF/VEGF induced increase in
vascular permeability is either through disruption or
change in localization of ZO-1 and VE-cadherin between
the endothelial cells [6,24-27]. Reports also show that
quiescent blood vessels contain a complex involving
VEGFR-2, VE-cadherin and β-catenin that are transiently
disrupted by VPF/VEGF injection. Blockade of Src pre-
vents disassociation of this complex and inhibits edema
accumulation [28,29]. Accordingly, we investigated
whether dopamine mediated inhibition of VPF/VEGF
induced vascular permeability is a result of its antagonism
of VPF/VEGF induced disruption of VEGFR-2, ZO-1, β-cat-
enin and VE-cadherin complex in the endothelial cells.
We also investigated if dopamine mediated modulation
of TJ and AJ proteins in the vascular endothelium in
response to VPF/VEGF were Src dependent.
Results
Dopamine inhibits VPF/VEGF mediated in vitro 
permeability
VPF/VEGF induced permeability significantly increased in
cultured HUVEC compared to the untreated cells. How-
ever, permeability significantly decreased when HUVEC
were pre-treated with 10 uM dopamine or the specific
dopamine D2 receptor agonist quinpirole before adminis-
tering VPF/VEGF (Figure 1). These results are consistent
with our previous in vivo findings where we demonstrated
that dopamine significantly and specifically inhibited
VPF/VEGF induced vascular permeability in the endothe-
lial cells [20-23]. Here we have focused on the possible
mechanism by which dopamine mediates this inhibition.
Dopamine modulates association of VEGFR-2 with Src
We demonstrated by immunoprecipitation in HUVEC
that Src remained constitutively associated with VEGFR-2,
and this association increased with VPF/VEGF treatment.
However pre-treatment with dopamine significantly
inhibited this association (Figure 2).
Activation of Src is dependent on tyrosine phosphorylation 
of VEGFR-2
Next we wanted to determine if activation of Src was
dependent on phosphorylation of VEGFR-2. At first we
confirmed efficacy of the kinase inhibitor (KINASE IV) by
treating HUVEC with the inhibitor with or without VPF/
VEGF and determined that phosphorylation of Y1175 on
VEGFR-2 was significantly decreased (Figure 3A), subse-
quently total tyrosine phosphorylation of VEGFR-2 was
also decreased (data not shown). Next HUVEC were pre-
treated with dopamine or kinase inhibitor with or without
VPF/VEGF. A basal level of phosphorylation at Y418 of Src
was observed in control cells. This was significantly
enhanced upon stimulation with VPF/VEGF. However,
pre-treatment with either dopamine or kinase inhibitor
caused a significant decrease in Y418 phosphorylation
and, therefore, activation [30] of Src (Figure 3B). Hence,
from our data thus far we infer that dopamine by decreas-
ing tyrosine phosphorylation on VEGFR-2 inhibited the
association of Src with VEGFR-2 resulting in inhibition of
Src activation.
VPF/VEGF mediated disruption of ZO-1 between the 
endothelial cells is abrogated by dopamine
Among the tight junctions, ZO-1 plays an important role
in maintaining vascular permeability [6,25]. Moreover,
recent reports also indicate that the VPF/VEGF inducedJournal of Molecular Signaling 2008, 3:14 http://www.jmolecularsignaling.com/content/3/1/14
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vascular leak is through the disruption and phosphoryla-
tion of ZO-1 between the endothelial cells [6,24-27,31].
We therefore determined whether the action of dopamine
is through suppression of VPF/VEGF mediated disruption
of ZO-1 in HUVEC. Our confocal microscopy experiments
demonstrated that although treatment with VPF/VEGF
disrupted ZO-1 between HUVEC in comparison to the
untreated controls (Figure 4A and 4B), pre-treatment with
either dopamine or quinpirole significantly abolished this
effect of VPF/VEGF (Figure 4C and 4D). Neither
dopamine nor quinpirole had any direct effects on the
integrity of ZO-1 between the endothelial cells (data not
shown), thereby confirming that the action of dopamine
was VPF/VEGF specific and it was through dopamine D2
receptors.
VPF/VEGF induced association between tight junction 
proteins, ZO-1 and occludin, are inhibited by dopamine
Occludin is an integral membrane protein closely associ-
ated with the tight junctions of epithelial and endothelial
cells. ZO-1 has been demonstrated to interact with the
transmembrane protein occludin, and it has a role in the
localization of occludin to tight junctions [32]. Lysates
from serum starved HUVEC were immunoprecipitated
with ZO-1 antibody and immunoblotted with antibody
against occludin. ZO-1 and occludin were constitutively
associated with each other. The association between ZO-1
and occludin increased significantly upon treatment with
VPF/VEGF (10 ng/ml), and this association was inhibited
by dopamine (10 μM) pre-treatment (Figure 5). Our data
clearly suggest that dopamine inhibits VPF/VEGF induced
association of ZO-1 with occludin and might explain the
inhibitory effect of dopamine in VPF/VEGF induced per-
meability.
Recent reports indicate that VPF/VEGF induced disruption
of ZO-1 in the endothelial cells is associated with
increased phosphorylation of ZO-1 in these cells [6,24].
We thus investigated whether treatment with dopamine
has any effect on VPF/VEGF induced increase in ZO-1
Dopamine inhibits VEGF induced in vitro permeability in HUVEC Figure 1
Dopamine inhibits VEGF induced in vitro permeability in HUVEC. Permeability is represented by relative fluores-
cence units as measured by a flux of FITC-Dextran across monolayer of HUVEC cultures in collagen-coated transwells. In the 
figure C-V is the control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/
VEGF (10 ng/ml) for 90 min, D+V is the HUVEC pre-treated with 10 μM dopamine for 15 min and then treated with VPF/
VEGF (10 ng/ml) for 90 min and Q+V is the HUVEC pretreated with 10 μM quinpirole for 15 min and then treated with VPF/
VEGF (10 ng/ml) for 90 min. Experiments were repeated three times in triplicate.
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phosphorylation in HUVEC. VPF/VEGF treatment signifi-
cantly increased ZO-1 phosphorylation in HUVEC in
comparison to untreated controls (Figure 6A). However,
cells pretreated with dopamine significantly inhibited
VPF/VEGF induced ZO-1 phosphorylation. A similar
effect was demonstrated with quinpirole (data not shown).
Our data suggest that the action of dopamine was through
dopamine D2 receptors, and we next questioned if this
observation could be mimicked in vivo.
It was observed that administration of either dopamine or
quinpirole into mice prior to VPF/VEGF treatment signif-
icantly inhibited ZO-1 phosphorylation (Figure 6B) in the
mesenteric vascular endothelium of these animals,
thereby validating our in vitro results in vivo. Overall, our
data clearly suggest that VPF/VEGF induced hyperpermea-
bility is controlled by dopamine through its D2R path-
ways, and it is mainly by controlling posttranslational
modification of tight junction proteins.
Dopamine modulates association between AJ and TJ 
proteins
VE-cadherin is specifically localized to the inter-endothe-
lial cell junction [13]. VE-cadherin inside the cell is linked
to  β-catenin that in turn promotes anchorage to the
cytoskeleton. Adherens junction, in particular VE-cad-
herin, is a target of the signaling pathway that increases
vascular permeability through VPF/VEGF [13,33-35]. In
addition to influencing the tight junction proteins, signals
from growth factors such as VPF/VEGF lead to changes in
the phosphorylation of adherens junction proteins like
VE-cadherin and associated catenins, thus weakening
endothelial cell-cell adhesion and increasing vascular per-
meability. In order to determine the role of dopamine, if
any, in affecting this complex, serum starved HUVEC were
pre-treated with or without dopamine before adding VPF/
VEGF (10 ng/ml). Then cell lysates were immunoprecipi-
tated with VE-cadherin antibody. Interestingly, we
observed that VEGFR-2, ZO-1, and β-catenin were consti-
tutively associated with VE-cadherin (Figure 7). Treatment
with VPF/VEGF significantly increased the association
between VE-cadherin and ZO-1; however, pre-treatment
with dopamine decreased the association (Figure 7). On
the other hand, neither VPF/VEGF nor dopamine treat-
ment induced any significant changes in the association
between VE-cadherin and β-catenin or VEGFR-2.
We then investigated whether treatment with dopamine
has any effect on VPF/VEGF induced increase in VE-cad-
herin and β-catenin phosphorylation in vascular endothe-
lium. VPF/VEGF treatment significantly increased VE-
cadherin and β-catenin phosphorylation in HUVEC as
compared to the untreated controls (Figure 8A and 8B).
Even so, dopamine pre-treatment completely inhibited
VE-cadherin and β-catenin phosphorylation in VPF/VEGF
treated cells. (Figure 8A and 8B).
Dopamine treatment alters VEGF/VPF induced VEGR-2 and c-Src association in HUVEC Figure 2
Dopamine treatment alters VEGF/VPF induced VEGR-2 and c-Src association in HUVEC. HUVEC extracts were 
immunoprecipitated with VEGFR-2 antibody and immunoblotted with Src and VEGFR-2 antibody. In the figure C-V is the con-
trol, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 
15 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine 
for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 min. Q-V is the HUVEC treated with 10 μM quinpirole for 15 
min and Q+V is the HUVEC pretreated with 10 μM quinpirole for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 
min. The figures are representative of three separate experiments with similar results.
C
-
V
C
+
V
D
-
V
D
+
V
IP: VEGFR-2, IB: Src
IP: VEGFR-2, IB: VEGFR-2
Src
VEGFR-2
F
o
l
d
 
a
s
s
o
c
i
a
t
i
o
n
 
o
f
 
S
r
c
/
 
V
E
G
F
R
-
2
0
1
2
3
4
C-V C+V D10-V D10+VJournal of Molecular Signaling 2008, 3:14 http://www.jmolecularsignaling.com/content/3/1/14
Page 5 of 11
(page number not for citation purposes)
Discussion
Here we demonstrate that the neurotransmitter dopamine
is a potent regulator of the important signaling cascades
controlling VPF/VEGF mediated vascular permeability
[3,6], an essential early step in angiogenesis [1,3]. These
results provide new mechanistic insights into the
dopamine-mediated inhibition of the activities of VPF/
VEGF. Src by regulating phosphorylation of key junctional
proteins such as VE-cadherin, b-catenin and occludin reg-
ulates endothelial permeability (11, 35). Furthermore
ZO-1 dissociates from occludin upon phosphorylation by
Src (11, 35). Src knockout mouse or otherwise blockade
of Src inhibits edema accumulation and thus permeability
[28,29]. Here we showed that dopamine inhibited VEGF
induced association and activation of Src with VEGFR-2.
We also showed that Src Y418 phosphorylation and hence
its activation was dependent upon tyrosine phosphoryla-
tion of VEGFR-2. Dopamine also inhibited the interaction
between TJ proteins and phosphorylation of proteins
involved in formation of the AJ complex in endothelial
cells. Association of occludin with ZO-1 and ZO-1 with
VE-cadherin was significantly inhibited by dopamine in
VEGF treated cells. VPF/VEGF induced phosphorylations
of VE-cadherin, β-catenin and ZO-1 were also inhibited by
dopamine treatment. Various studies have reported that
phosphorylation of VE-cadherin or β-catenin correlate
with increased endothelial permeability [11,34]. There-
fore, we infer that dopamine by decreasing tyrosine phos-
phorylation of VEGFR-2 inhibits association of Src with
VEGFR-2 resulting in inhibition of Src activation. This
reduced Src activation then results in decreased phospho-
rylation of ZO-1, VE-cadherin and β-catenin leading to
stabilization of junctional complexes and restoration of
endothelial barrier function.
VPF/VEGF induced VEGFR-2 phosphorylation is required for Src phosphorylation Figure 3
VPF/VEGF induced VEGFR-2 phosphorylation is required for Src phosphorylation. (A) Kinase inhibitor (250 nM) 
inhibits VPF/VEGF induced VEGFR-2 Y1175 phosphorylatin. In the figure C-V is control, HUVEC without any VPF/VEGF or 
dopamine treatment, C+V is the HUVEC treated with only VEGF (10 ng/ml) for 15 min, C+KI+V is the HUVEC pretreated 
with kinase inhibitor (KINASE IV) for 30 min and treated with VPF/VEGF (10 ng/ml) for another 15 min (B) Pre-treatment of 
HUVEC with kinase inhibitor inhibits VEGF induced Src Y418 phosphorylation. In the figure C-V is control, HUVEC without 
any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 15 min, C+KI+V is the 
HUVEC pre-treated with kinase inhibitor for 30 min and treated with VPF/VEGF (10 ng/ml) for another 15 min and D+V is the 
HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 min. The figures are 
representative of three separate experiments with similar results.
C
-
V
C
+
V
C
+
K
I
+
V
D
+
V
A. B.
IB: pSrc 418
IB: Src
p-Src
Src
C
-
V
C
+
V
C
+
K
I
+
V
IB: pVEGFR-2 (1175)
pVEGFR-2
0
0.5
1
1.5
2
2.5
C-V C+V C+K250+V D10+V
F
o
l
d
 
o
f
 
p
-
S
r
c
 
(
4
1
8
)Journal of Molecular Signaling 2008, 3:14 http://www.jmolecularsignaling.com/content/3/1/14
Page 6 of 11
(page number not for citation purposes)
Confocal microscopy images of tight junctions in HUVEC Figure 4
Confocal microscopy images of tight junctions in HUVEC. (A) normal ZO-1 in untreated control HUVEC (B) dis-
rupted ZO-1 in VPF/VEGF (10 ng/ml) treated HUVEC (C) dopamine (10 μM) + VPF/VEGF (10 ng/ml) treated HUVEC shows 
that pre-treatment with dopamine inhibits the ZO-1 disrupting property of VPF/VEGF (D) quinpirole (10 μM) + VPF/VEGF (10 
ng/ml) treated HUVEC shows that pre-treatment with quinpirole inhibits the ZO-1 disrupting property of VPF/VEGF. The fig-
ures are representative of three separate experiments with similar results. Average intensity of ZO-1 staining for each cell was 
measured using metamorph software (version 7, Molecular Devices Inc., Toronto, Canada). Scale bar, 20 μm.
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Effect of dopamine on ZO-1 and occludin association Figure 5
Effect of dopamine on ZO-1 and occludin association. Immunoprecipitation experiment showed ZO-1 and occludin 
were constitutively associated with each other. In the figure C-V is the control, HUVEC without any VPF/VEGF or dopamine 
treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min, D-V is the HUVEC treated with 10 μM 
dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF 
(10 ng/ml) for 5 min. The figures are representative of three separate experiments with similar results.
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Our in vitro results were corroborated by our experiment
in vivo in that VPF/VEGF induced tyrosine phosphoryla-
tion of ZO-1 was significantly inhibited by pre-treatment
with dopamine or quinpirole. These results justify our
previous report where we showed that mice deficient in
peripheral dopamine had increased microvascular perme-
ability following VPF/VEGF administration [21,23]. Our
results are in accordance with a recent report that states
that hypothermia induced loss of endothelial barrier func-
tion can be restored by dopamine pre-treatment [36]. The
effect of dopamine thus far is selective for VPF/VEGF, as
dopamine does not affect vascular permeability enhanc-
ing action of bradykinin or platelet-activating factor [20].
Furthermore endothelial cells expressed D1, D2 and D5
dopamine receptors as determined by western blot and
RT-PCR (data not shown); however, the permeability
inhibiting functions were mediated mostly by the
dopamine D2  receptors. In a previous report we had
shown that the D1 agonist SKF38393 or two other cate-
cholamine vasopressors, epinephrine and norepine-
phrine, which do not interact with D2 receptors, did not
alter or affect tumor ascites [20].
Finally, our result is significant because recent clinical
efforts are underway to pharmacologically block VPF/
VEGF mediated leakage in patients after acute myocardial
infarction [6]. This therapeutic effort in turn may have a
major impact on reducing tissue injury and thereby mini-
mize the long-term consequences in this group of patients
[6]. A similar approach may become available for stroke
patients or individuals with retinal edema, where VPF/
Effect of dopamine on VPF/VEGF-induced phosphorylation of ZO-1 in vitro and in vivo Figure 6
Effect of dopamine on VPF/VEGF-induced phosphorylation of ZO-1 in vitro and in vivo. (A) Decreased VPF/VEGF-
induced phosphorylation of ZO-1 in HUVEC incubated with dopamine (10 μM) for 15 min before VPF/VEGF (10 ng/ml) treat-
ment. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with 
only VPF/VEGF (10 ng/ml) for 5 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pre-
treated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 5 min. The figures are representative 
of three separate experiments with similar results. (B) Increased VPF/VEGF-induced phosphorylation of ZO-1 in mesenteric 
vascular endothelium (MVE) of mice treated with 500 ng of VPF/VEGF [C+V] and decreased VPF/VEGF-induced phosphoryla-
tion of ZO-1 in MVE of mice treated with either quinpirole (10 mg/kg i.p.) [Q+V] or dopamine (50 mg/kg i.p.) [D+V] 10 min 
before VPF/VEGF (500 ng) treatment were detected. C-V is the untreated control.
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VEGF induced enhanced vascular permeability plays an
important pathogenic role [6]. Blocking VPF/VEGF medi-
ated vascular leakage can also have a critical effect in can-
cer patients by reducing metastatic entry of tumor cells
into or out of the vascular circulation [1,3,6]. Most impor-
tantly, dopamine has been used in the clinics for several
years in the treatment of cardiogenic shock complicating
myocardial infarction [37]. Taken together, our study sug-
ZO-1, β-catenin, VE-Cadherin and VEGFR-2 are in the same immunocomplex Figure 7
ZO-1, β-catenin, VE-Cadherin and VEGFR-2 are in the same immunocomplex. Immunoprecipitation with VE-cad-
herin antibody showed constitutive association between VE-cadherin, VEGFR-2, β-catenin and ZO-1. In the figure C-V is con-
trol, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 
min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 
15 min and then treated with VPF/VEGF (10 ng/ml) for 5 min. The figures are representative of three separate experiments 
with similar results.
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Dopamine pre-treatment inhibits VPF/VEGF-induced phosphorylation of β-catenin and VE-cadherin Figure 8
Dopamine pre-treatment inhibits VPF/VEGF-induced phosphorylation of β-catenin and VE-cadherin. HUVEC 
were pretreated with dopamine (10 μM) 15 min before VPF/VEGF (10 ng/ml) treatment. In the figure C-V is control, HUVEC 
without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min and D+V 
is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 30 min. The cell 
extracts were immunoprecipitated (IP) with anti-phosphotyrosine antibodies and immunoblotted (IB) with either (A) anti-β-
catenin or (B) anti-VE-cadherin antibodies. The figures are representative of four separate experiments with similar results.Journal of Molecular Signaling 2008, 3:14 http://www.jmolecularsignaling.com/content/3/1/14
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gests a novel and a new therapeutic role for dopamine in
these patients. In addition, this report also identifies the
molecular mechanism of dopamine's influence on VPF/
VEGF induced permeability.
Conclusion
The main conclusions are: 1. We found VEGFR-2 to be
part of a multi-protein complex involving ZO-1, VE-cad-
herin and β-catenin. 2. VPF/VEGF induced phosphoryla-
tions of VE-cadherin, β-catenin and ZO-1 were inhibited
by dopamine treatment. 3. Association of occludin with
ZO-1 and ZO-1 with VE-cadherin were significantly inhib-
ited by dopamine in VEGF treated cells. 4. Furthermore
dopamine inhibited VPF/VEGF induced activation and
association of Src with VEGFR-2.
Methods
Reagents
ZO-1 antibody (sc-10804), VE-cadherin antibody (sc-
6458), β-catenin antibody (sc-7963), Occludin antibody
(sc-8144), Src antibody (sc-5266) and VEGFR-2 (sc-504)
antibody were from Santa Cruz Biotechnology, Califor-
nia, USA. Anti-phosphotyrosine monoclonal antibody
(4G10) and phospho-Src [pTyr418] antibody were from
Biosource International, Inc., CA; and AlexaFlour 546 sec-
ondary antibody was from Molecular Probes, OR. Aclar®
fluoropolymer film was from Honeywell, NJ. Dopamine
hydrochloride for in vitro, quinpirole and all other chem-
icals if not mentioned were from Sigma-Aldrich, MO.
Dopamine hydrochloride for in vivo use was from Abbott
Laboratories, IL. VPF/VEGF was from R &D Systems, MN.
VEGF receptor 2 Kinase inhibitor IV was from Calbiochem
(Cat # 676489).
Animals
Five- to six-week-old NIHBNX-MMC mice were purchased
from the Taconic Farms, Germantown, NY. The animals
were caged in plastic tubs covered with stainless steel tops
at a temperature between 23 and 25°C, humidity level of
50 ± 10%, and a 12:12-h light-dark cycle. The mice were
given ad libitum water and food.
Immunofluorescence
2 × 103 HUVEC were seeded on collagen coated Lab-Tek
chamber slides. After four days of culture when these cells
were confluent, they were serum starved for 24 hours.
Thereafter, these cells were treated with either dopamine
(10 μM) or a specific dopamine D2 receptor agonist quin-
pirole (10 μM) [20], followed 10 min later by addition of
20 ng of VPF/VEGF for 1 h. Thereafter, the cells were
washed with PBS and fixed in 4% paraformaldehyde
(PFA). Slides were again re-washed with PBS, blocked in
10% goat serum, and stained with anti-ZO-1 antibody
(1:100 dilution, except phosphotyrosine antibodies were
used at 1:1000) in 1% goat serum for 2 h. Finally, the
slides were washed in PBS and incubated 1 hr in Alexa-
Flour 546 secondary antibody at a dilution of 1:200 fol-
lowed by postfixing in 4% PFA and mounted in
Vectashield (Vector Labs). Confocal microscopy was per-
formed using a Zeiss LSM 510 confocal laser scan micro-
scope with C-Apochromat 63x/NA1.2 water-immersion
lense. Absence of signal crossover was established using
single-labeled samples [20,38].
Immunoprecipitation and Western blot analysis in vitro
HUVEC lysates in NP-40 buffer supplemented with pro-
tease inhibitor cocktail were immunoprecipitated with
different antibodies (1:100 dilutions) and immunocom-
plexes were captured on protein A-agarose beads. Thereaf-
ter, samples were subjected to SDS-PAGE and then
transferred to polyvinyl difluoride membranes and
immunoblotted. Antibody-reactive bands were finally
detected by enzyme-linked chemiluminescence (Amer-
sham) and quantified by laser densitometry [20-23].
In vitro permeability assay
The assay was performed according to established manu-
facturer's protocol, Catalog# ECM 640, Chemicon Inter-
national Inc., CA. Briefly, 2 × 105 HUVEC in 200 μL were
seeded onto collagen coated inserts in 24 well plates. 700
μL complete EBM medium was added to the plates. The
cells were allowed to grow for 4–5 days until a monolayer
was formed. The medium was replaced with phenol free
starving EBM medium containing 0.1% FBS for 12–14
hrs. The respective inserts containing HUVEC were then
pre-treated with 10 μM Dopamine or Quinpirole for 15
min. Subsequently, FITC-Dextran containing medium
(phenol free EBM) with or without VEGF at 10 ng/ml was
added. Fluorescence was measured after 90 min on the
Spectra Flour Plus using excitation and emission wave-
lengths of 485 nm/535 nm.
Collection of Mesentery from Mice and 
Immunoprecipitation, Immunoblotting of the mesenteric 
homogenates
Animal protocols were approved by the Mayo Clinic Insti-
tutional Animal Care and Use Committee. Mesenteries
were collected from normal 5–6 week-old NIHBNX-MMC
mice and treated either with the anti-angiogenic dose of
dopamine (50 mg/kg i.p) or specific dopamine D2 recep-
tor agonist quinpirole (10 mg/kg ip) 10 min before VPF/
VEGF injection. Briefly, normal mice previously treated
with either dopamine or D2 receptor agonist was injected
i.p. with 500 ng of recombinant human VPF/VEGF in 1 ml
of HBSS. After 1 h, these animals were anesthetized with
an injection of 0.4–0.75 mg/g ip Avertin and were eutha-
nized by decapitation. The abdomen was then opened,
loops of the small intestine were exteriorized, and mesen-
tery windows including fatty vascular portions were dis-
sected free and transferred to HBSS at 4°C. Four to sixJournal of Molecular Signaling 2008, 3:14 http://www.jmolecularsignaling.com/content/3/1/14
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mesenteric windows, each roughly 1–3 cm2 in area, could
be isolated from a single mouse.
Thereafter, mesenteries were homogenized immediately
upon collection with a polytron tissue homogenizer
(model PCU II; Kinematica AG, Switzerland) in a precipi-
tation assay buffer [50 mM Tris (pH 7. 5), 0.25% sodium
deoxycholate, 1% NP40, 150 mM NaCl, 1 ml Na3 VO4, 2
mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 ug/
ml leupeptin, 0.5% aprotinin, and 2 mM pepstatin A for
10 s at 4°C. Homogenates were then centrifuged for 5 min
at 4°C, and supernatants were immunoprecipitated with
different antibodies (1:100 dilution), and immunocom-
plexes was captured on protein A-agarose beads. Finally,
samples were subjected to SDS-PAGE and then transferred
to polyvinyl difluoride membranes and immunoblotted.
Antibody-reactive bands was detected by enzyme-linked
chemiluminescence (Amersham) and quantified by laser
densitometry [32]. Since these animals were severely
immunocompromised (T, NK and B cell deficient), the
chance of any immune reaction mediated changes in the
vascular permeability (which includes edema) following
exogenous VPF/VEGF treatment was negligible.
Statistics
Differences among groups were evaluated by ANOVA and
the unpaired Student's t-test or Dunn's multiple-compari-
son test. Statistical significance was assigned when P <
0.05 [20-23]. Error bars were given on the basis of stand-
ard deviation (SD) values.
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